Physician profile
Guy E Mcelwain
NPI 1629049804
$968.91
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $305 · 2020: $226 · 2021: $438.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $273.36 | 2019-2021 | |
| Abbvie INC. | $122.35 | 2019-2021 | |
| Astellas Pharma US INC | $107.70 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $80.24 | 2019-2020 | |
| Novo Nordisk INC | $70.88 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $69.31 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $58.12 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.62 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.20 | 2020 | |
| Merck Sharp & Dohme LLC | $28.83 | 2019-2021 | |
| Amgen INC. | $26.17 | 2019 | |
| Daiichi Sankyo INC. | $24.93 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.83 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $11.37 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Guy Mcelwain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.